Molplex lowers the average cost of discovering a drug candidate from £20M to less than £1M and builds discovery project pipelines designed to be commercially attractive to partners and investors. Molplex is driven by 2 ambitions:
– De-risked R&D. Lower the average costs of drug R&D by radically reducing the 99% failure rate, not by getting people to walk round the lab faster.
– Open Innovation R&D. Enabling good scientists wherever they are in the world to form effective operational R&D teams with no set up or fixed costs and no requirements for glass and marble palaces.